

DAFTAR PUSTAKA

- Asher, V., Lee, J., & Bali, A. (2012). Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. *Med. Oncol.* 29 : 2005–2009.
- Bachmann, C., Bachmann, R., Fend, F., & Wallwiener, D. (2016). Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment. *J. Cancer.* 7 : 2241–2246.
- Bandera, E. V., Lee, V.S., Qin, B., Rodriguez-Rodriguez, L., Powell, C.B., & Kushi, L.H. (2017). Impact of body mass index on ovarian cancer survival varies by stage. *Br. J. Cancer.* 117 : 282–289.
- Berek, J.S., Kehoe, S.T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *Int. J. Gynecol. Obstet.* 143 : 59–78.
- Brieger, K.K., Phung, M.T., Mukherjee, B., Bakulski, K.M., Anton-Culver, H., Bandera, E. V., *et al.* (2022). High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. *Cancer Epidemiol. Biomarkers Prev.* 31 : 443–452.
- Canreg.fkkmk (2022). Distribusi Kasus Kanker RSUP Dr. Sardjito/ FK-KMK UGM 2008-2019 [Cited 2023 Jun 09]. Available from : <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/>.
- Castano, M., Tomás-Pérez, S., González-Cantó, E., Aghababayan, C., Mascarós-Martínez, A., Santonja, N., *et al.* (2023). Neutrophil Extracellular Traps and Cancer: Trapping Our Attention with Their Involvement in Ovarian Cancer. *Int. J. Mol. Sci.* 24(6): 5995.
- Chen, G., Zhu, L., Yang, Y., Long, Y., Li, X., & Wang, Y. (2018). Prognostic role of neutrophil to lymphocyte ratio in ovarian cancer: A meta-analysis. *Technol. Cancer Res. Treat.* 17: 1-8.
- Dao, F., Schlappe, B.A., Tseng, J., Lester, J., Nick, A.M., Lutgendorf, S.K., *et al.* (2016). Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecol. Oncol.* 141 : 260–263.
- Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., *et al.* (2017). Age is associated with prognosis in serous ovarian carcinoma. *J. Ovarian Res.* 10:36.
- Deng, K., Yang, C., Tan, Q., Song, W., Lu, M., Zhao, W., *et al.* (2018). Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. *Gynecol. Oncol.* 150 : 460–465.
- Fagotti, A., Ferrandina, M.G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., *et al.* (2020). Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer. *Int. J. Gynecol. Cancer* 30 : 1657–1664.
- Feng, Z., Wen, H., Bi, R., Ju, X., Chen, X., Yang, W., *et al.* (2016). Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer. *PLoS One* 11(5) :1561.
- Fortner, R.T., Trewin-Nybråten, C.B., Paulsen, T., & Langseth, H. (2023). Characterization of ovarian cancer survival by histotype and stage: A

- nationwide study in Norway. *Int. J. Cancer* 153 : 969–978.
- Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., *et al.* (2022). Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. *Cancer Epidemiol.* 76:102074.
- Himpunan Obstetri Ginekologi Indonesia. 2018 *Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi*.PNPK HOGI, Jakarta.
- Hirst, J., Crow, J., & Godwin, A. (2018). Ovarian Cancer Genetics: Subtypes and Risk Factors, in: Ovarian Cancer - From Pathogenesis to Treatment. *InTech.* 10:5772.
- Hu, Q., Hada, A., Han, L. 2020. Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer. *J. Ovarian Res.*, 13(1):78.
- Hufnagel, D.H., Cozzi, G.D., Crispens, M.A., & Beeghly-Fadiel, A. (2020). Platelets, thrombocytosis, and ovarian cancer prognosis: Surveying the landscape of the literature. *Int. J. Mol. Sci.* 21(21):8169.
- John-Olabode, S.O., Okunade, K.S., Olorunfemi, G., Soibi-Harry, A., Rimi, G., Osunwusi, B., *et al.* (2021). Pretreatment Neutrophil-to-Lymphocyte Ratio: A Prognostic Biomarker of Survival in Patients With Epithelial Ovarian Cancer. *Cureus.* 13(7):16429.
- Kwon, B.S., Jeong, D.H., Byun, J.M., Lee, T.H., Choi, K.U., Song, Y.J., *et al.* (2018). Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. *J. Cancer* 9 : 1127–1134.
- Lee, Y.J., Chung, Y.S., Lee, J.Y., Nam, E.J., Kim, S.W., Kim, S., *et al.* (2019). Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. *Cancer Med.* 8 : 564–571.
- Lheureux, S., Braunstein, M., & Oza, A.M. (2019). Epithelial ovarian cancer: Evolution of management in the era of precision medicine. *CA. Cancer J. Clin.* 69 : 280–304.
- Liu, H., Xu, Y., Ji, J., Dong, R., Qiu, H., & Dai, X. (2020). Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population–based analysis. *Oncol. Lett.* 19 : 1947–1957.
- Liu, S., Wu, M., & Wang, F. (2021). Research progress in prognostic factors and biomarkers of ovarian cancer. *J. Cancer.* 12(13) : 3976-3996.
- Lukanović, D., Kobal, B., & Černe, K. (2022). Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. *Reprod. Med.* 3 : 127–140.
- Marth, C., Abreu, M.H., Andersen, K.K., Aro, K.M., de Lurdes Batarda, M., Boll, D., *et al.* (2022). Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study. *Cancer.* 128 : 3080–3089.
- Matz, M., Coleman, M.P., Sant, M., Chirlaque, M.D., Visser, O., Gore, M., *et al.* (2017). The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol. Oncol.* 144 : 405–413.
- Mehra, P., Aditi, S., Prasad, K.M., & Bariar, N. k (2023). Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. *Cureus.*

15(4) : 38273.

- Mleko, M., Pitynski, K., Pluta, E., Czerw, A., Sygit, K., Karakiewicz, B., *et al.* (2021). Role of systemic inflammatory reaction in female genital organ malignancies – state of the art. *Cancer Manag. Res.* 13:5491-5508.
- Morrison, J., Swanton, A., Collins, S., & Kehoe, S. (2007). Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. *Cochrane Database Syst. Rev.* 17(4) : 5343.
- Peres, L.C., Cushing-Haugen, K.L., Köbel, M., Harris, H.R., Berchuck, A., Rossing, M.A., *et al.* (2019). Invasive epithelial ovarian cancer survival by histotype and disease stage. *J. Natl. Cancer Inst.* 111 : 60-68.
- Prabowo, A., Tjokropawiro, B.A., & Utomo, B. (2022). Correlation between clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia. *Bali Med. J.* 11 : 807–812.
- Raunkaewmanee, S., Tangjitgamol, S., Manusirivithaya, S., Srijaipracharoen, S., & Thavaramara, T. (2012). Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J. Gynecol. Oncol.* 23 : 265–273.
- Rifqi, R., Alkaff, M.L., & Pradjatmo, H. (2023). Hubungan Nilai Rasio Neutrofil-Limfosit Pra Pembedahan dengan Prognosis Kanker Ovarium Jenis Epitelial di RSUP Dr. Sardjito. *J. Kesehat. Reproduksi* 10 : 75-82.
- Rosales, C. (2018). Neutrophil: A cell with many roles in inflammation or several cell types? *Front. Physiol.* 9 : 113
- Sambasivan, S. (2022). Epithelial ovarian cancer: Review article. *Cancer Treat. Res. Commun.* 33:100629
- Sanna, E., Tanca, L., Cherchi, C., Gramignano, G., Oppi, S., Chiaia, M.G., *et al.* (2021). Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer. *Diagnostics.* 11(7) : 1298.
- Sastra, W.I.G., Aditya, P.P.K., Gradiyanto, O.E., & Ketut, S. (2022). Predictive value of preoperative inflammatory markers and serum CA 125 level for surgical outcome in Indonesian women with epithelial ovarian cancer. *Cancer Biomarkers* 34 : 123–129.
- Scott, B. (2023). A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022. *EMJ Oncol.* 2:12.
- Sheinenzon, A., Shehadeh, M., Michelis, R., Shaoul, E., & Ronen, O. (2021). Serum albumin levels and inflammation. *Int. J. Biol. Macromol.* 184 : 857–862.
- So, K.A., Hong, J.H., Jin, H.M., Kim, J.W., Song, J.Y., Lee, J.K., *et al.* (2014). The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: A retrospective cohort study. *Gynecol. Oncol.* 132 : 551–555.
- Song, Q., Xu, S.X., Wu, J.Z., Ling, L., Wang, S., Shu, X.H., *et al.* (2023). The preoperative platelet to neutrophil ratio and lymphocyte to monocyte ratio are superior prognostic indicators compared with other inflammatory biomarkers in ovarian cancer. *Front. Immunol.* 14:117740.
- Sun, H., Yan, L., Chen, H., Zheng, T., Zhang, Y., & Wang, H. (2020). Development of a nomogram to predict prognosis in ovarian cancer: A SEER-based study.

- Transl. Cancer Res.* 9 : 5829–5842.
- Sysmex (2024). The white blood cell differential count application ‘DIFF’ [Cited 2024 Aug 07]. Available from : <https://www.sysmex-europe.com/academy/knowledge-centre/technologies/white-blood-cell-differential-count-application-diff/>.
- Tang, Q., Li, X., & Sun, C.R. (2024). Predictive value of serum albumin levels on cancer survival: a prospective cohort study. *Front. Oncol.* 14:1323192.
- Team - RSUP dr. Sardjito Yogyakarta (2022). Mengenal Kanker Ovarium, The Silent Killer [Cited 2023 Sept 19]. Available from : https://yankes.kemkes.go.id/view_artikel/1043/mengenal-kanker-ovarium-the-silent-killer#:~:text=Menurut data Global Cancer Incidence,angka kematian mencapai 9.581 kasus.
- Vázquez Rojo, J., Vázquez Reguera, J., & Sánchez del Río, A. (2024). Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer. *Rev. Colomb. Obstet. Ginecol.* 75(1) : 4046.
- Wang, Y., Liu, P., Xu, Y., Zhang, W., Tong, L., Guo, Z., *et al.* (2015). Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. *Cancer Chemother. Pharmacol.* 75 : 255–262.
- Williams, K.A., Labidi-Galy, S.I., Terry, K.L., Vitonis, A.F., Welch, W.R., Goodman, A., *et al.* (2014). Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. *Gynecol. Oncol.* 132 : 542–550.
- Winarno, G.N.A., Pasaribu, M., Susanto, H., Nisa, A.S., Harsono, A.B., Yuseran, H., *et al.* (2021). The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer. *Asian Pacific J. Cancer Prev.* 22 : 1561–1566.
- Winarto, H., Welladatika, A., Habiburrahman, M., Purwoto, G., Kusuma, F., Utami, T.W., *et al.* (2022). Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience. *Open Access Maced. J. Med. Sci.* 10 : 265–280.
- Yang, Z., Gu, J.-H., Guo, C.-S., Li, X.-H., & Yang, W.-C. (2017). Oncotarget 46414 www.impactjournals.com/oncotarget Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies, *Oncotarget.* 8(28) : 46416–46424.
- Zhang, H., Huo, Q., Huang, L., Cheng, Y., Liu, Y., & Bao, H. (2019). Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration. *Biomed Res. Int.* 2019:8107906.
- Zhang, W., Zhang, Z., & Qian, L. (2024). Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis. *World J. Surg. Oncol.* 22 : 8.
- Zhou, Y., Wang, A., Sun, X., Zhang, R., & Zhao, L. (2023). Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database. *Front. Oncol.* 13:1257615.